Glucocorticoid-induced Osteoporosis.
10.3904/kjm.2017.92.2.142
- Author:
Ju Yang JUNG
1
;
Chang Hee SUH
Author Information
1. Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea. chsuh@ajou.ac.kr
- Publication Type:Review
- Keywords:
Glucocorticoid;
Osteoporosis;
Bone mineral density
- MeSH:
Absorptiometry, Photon;
Bone Density;
Denosumab;
Diphosphonates;
Epidemiology;
Glucocorticoids;
Humans;
Osteogenesis;
Osteoporosis*;
Porosity;
Risk Assessment;
Teriparatide
- From:Korean Journal of Medicine
2017;92(2):142-149
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Osteoporosis is a common adverse event among patients on glucocorticoid therapy. Glucocorticoids reduce bone formation and increase cortical porosity in proportion to the dose and duration of glucocorticoid use. While the epidemiology of glucocorticoid-induced osteoporosis has been well characterized, its pathophysiology and effective management remain unclear. Several recommendations for glucocorticoid-induced osteoporosis are used to determine which patients on long-term glucocorticoid treatment to treat and when. The fracture risk can be assessed using dual-energy X-ray absorptiometry and the Fracture Risk Assessment Tool algorithm, along with other clinical factors. The management of glucocorticoid-induced osteoporosis includes anti-osteoporotic therapy and measures to prevent bone loss. Bisphosphonates are currently the first choice treatment, with teriparatide and denosumab being alternatives.
